Dual components of optimal asthma therapy: Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids

Ronnann Naedele-Risha, Paul Dorinsky, Timothy Craig

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The authors describe the scientific rationale for using an inhaled corticosteroid with an inhaled long-acting β2-agonist. They discuss the clinical trials demonstrating that using an inhaled corticosteroid with an inhaled long-acting β2-agonist provides greater overall asthma control compared with increasing the dose of inhaled corticosteroid. In addition, they review the clinical trials comparing the addition of a leukotriene modifier to an inhaled corticosteroid versus using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Discussion also includes descriptions of trials showing reduced exacerbations of asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist. Finally, the authors provide evidence for the ability to detect deteriorating asthma when using an inhaled corticosteroid with an inhaled long-acting β2-agonist, and they provide a comparison of salmeterol and formoterol, two long-acting β2-agonists.

Original languageEnglish (US)
Pages (from-to)526-533
Number of pages8
JournalJournal of the American Osteopathic Association
Volume101
Issue number9
StatePublished - Oct 1 2001

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Fingerprint Dive into the research topics of 'Dual components of optimal asthma therapy: Scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids'. Together they form a unique fingerprint.

Cite this